Practice Update: Review of Anticonvulsant Therapy

@article{Chong2016PracticeUR,
  title={Practice Update: Review of Anticonvulsant Therapy},
  author={Derek J. Chong and Andrew M Lerman},
  journal={Current Neurology and Neuroscience Reports},
  year={2016},
  volume={16},
  pages={1-14}
}
Since 2010, the Food and Drug Administration has approved the use of four new anti-epilepsy drugs (AEDs) for the treatment of epilepsy in the USA: clobazam (Onfi), ezogabine (Potiga), perampanel (Fycompa), and eslicarbazepine (Aptiom) as well as two extended release formulations, topiramate ER (Qudexy XR and Trokendi) and oxcarbazepine ER (Oxtellar). This not only provides practitioners ample choice to match medication profiles to their patients’ preferences and co-morbidities better, but also… Expand
View on Springer
ncbi.nlm.nih.gov
27 Citations
Highly Influential Citations
1
Background Citations
8
Methods Citations
1

27 Citations

Citation Type

Citation Type

Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents
TLDR
The mechanism of action, pharmacokinetics, drug–drug interactions, and safety/tolerability profiles of the main AEDs currently used in children and adolescents are reviewed, paying particular regard to issues of relevance when treating this patient population. Expand
Antiepileptic Drugs in Children : Current Concept
  • Jeehun Lee
  • Medicine
  • Journal of Korean Neurosurgical Society
  • 2019
TLDR
In general, AED therapy following a first unprovoked seizure in children is not recommended, however, treatment should be considered after a second seizure, and guidelines for monitoring adverse effects are outlined. Expand
The pharmacological management of Lennox-Gastaut syndrome and critical literature review
TLDR
Currently, cannabidiol has provided high evidence of efficacy against LGS seizures; however, these data must be confirmed by long-term extensive studies and by trials comparing different AEDs, one to each other. Expand
Miscellaneous Therapeutic Drugs
TLDR
The final group of drugs discussed in this chapter are the non-narcotic analgesics and include aspirin, nonsteroidal anti-inflammatory agents, and acetaminophen. Expand
Epilepsy treatment in adults and adolescents: Expert opinion, 2016
TLDR
A "snapshot" of the clinical practices of experts in the treatment of epilepsy is provided, which suggests options that the clinician should consider to achieve best practice. Expand
Perampanel: Does it have broad‐spectrum potential?
TLDR
Perampanel is a potentially broad‐spectrum antiepileptic drug with a novel mechanism of action that may be a useful addition for patients with epilepsy with various seizure types. Expand
Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
TLDR
Similar AED reporting rates were observed for the AG and generic comparisons for most outcomes and drugs, suggesting that brands and generics have similar reporting rates after accounting for generic perception biases. Expand
Diagnostic implications of review-of-systems questionnaires to differentiate epileptic seizures from psychogenic seizures
TLDR
It is confirmed that patients with PNES with and without comorbid ES report more symptoms on a population level than patients with epilepsy or PSLE and suggested that the RoSQ may help differentiate PNES from ES only when, based on other information, the pre-test probability of PNES is at least 50%. Expand
Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
  • Yang-Ming Zhang, Haiyan Xu, +8 authors F. Nan
  • Chemistry, Medicine
  • Journal of medicinal chemistry
  • 2021
TLDR
The discovery of HN37 (pynegabine), which demonstrated satisfactory chemical stability upon deleting the ortho liable -NH2 group and installing two adjacent methyl groups to the carbamate motif, has progressed to clinical trial in China for epilepsy treatment. Expand
Design, synthesis, in vivo and in silico evaluation of phenacyl triazole hydrazones as new anticonvulsant agents.
TLDR
In vivo anticonvulsant evaluation of synthesized compounds by using MES and PTZ tests revealed that they are more effective in MES model respect to PTZ test, and the isonicotinic acid hydrazide derivative 3h showed the best profile of activity in both models. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 100 REFERENCES
Update on Anticonvulsant Drugs
TLDR
There has been much interest surrounding medications for epilepsy and their possible association with osteoporosis, safety during pregnancy, biological equivalence to generic versions, and possibly association with higher rates of suicidality. Expand
Experience in the use of clobazam in the treatment of Lennox–Gastaut syndrome
TLDR
Clobazam appears to have a safe profile and sustained effectiveness over the first 3 years of use in LGS and other epilepsy syndromes with intractable seizures, which makes it a viable long-term treatment option. Expand
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome
  • M. Faulkner
  • Medicine
  • Therapeutics and clinical risk management
  • 2015
TLDR
Data from an open-label extension trial have confirmed that clobazam is efficacious for the treatment of seizures associated with LGS, particularly atonic seizures (drop seizures), over the long term. Expand
Clobazam in the Treatment of Epilepsy: A Review of the Literature
TLDR
Clobazam appears to be a useful treatment for epilepsy as intermittent or short‐term add‐on therapy; but it should also be tried as long‐term therapy in some situations, especially as add-on therapy for patients with refractory epilepsy, as add‐ on or monotherapy for Patients with anxiety, or in some women in association with oral contraceptives. Expand
Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
TLDR
The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary. Expand
Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
TLDR
The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary. Expand
The use of monotherapy in patients with epilepsy: An appraisal of the new antiepileptic drugs
TLDR
The advantages of using AEDs in monotherapy in patients with newly diagnosed and refractory epilepsies are reviewed, focusing on the individual properties of the drugs that may make them more appropriate in various patient groups. Expand
Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs
TLDR
Overall, the new AEDs are less interacting primarily because many are renally excreted or not hepatically metabolised and most do not (or minimally) induce or inhibit hepatic metabolism. Expand
Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study.
TLDR
This study shows that LEV and PGB represent valuable monotherapy options in this setting, with very good antiepileptic efficacy and an acceptable tolerability profile, and provides important data for the design of a phase III trial. Expand
Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
TLDR
Ezogabine is a newly approved anticonvulsant for adjunctive therapy in partial-onset seizures in adults with a novel mechanism of action, activating low-threshold voltage-gated potassium channels, limiting its potential for drug-drug interactions. Expand
...
1
2
3
4
5
...